

SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Drug Requested: Ragwitek[®] (Short Ragweed Pollen Allergen Extract)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code: _____

Weight: _____ Date: _____

Recommended Dosage: Dissolve one tablet under the tongue daily for 3 consecutive years

- Ragweed pollen season = Mid-August to October; the duration of authorization will be for a 12-month period and will remain active for 3 consecutive years

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Length of Authorization: 3 years

- Medication is prescribed by or in consultation with an allergist or immunologist
- Member must be between the ages of 5 and 65 years old
- Treatment will be initiated at least 12 weeks before the expected onset of ragweed pollen season and will be continued throughout the ragweed pollen season

(Continued on next page)

- ❑ Member has a diagnosis of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis confirmed by **ONE** of the following (skin test or in vitro testing for short ragweed pollen-specific IgE antibodies results **must** be submitted with request):
 - ❑ Positive skin prick test for short ragweed pollen antigen or cross-reactive allergen
 - ❑ Positive in vitro testing for pollen-specific IgE antibodies for short ragweed pollen antigen or cross reactive allergen
- ❑ Member has had trial and inadequate symptom control with at least **TWO** of the following within the past 12 months (**verified by chart notes or pharmacy paid claims**):
 - ❑ Intranasal corticosteroid (e.g., fluticasone, budesonide, triamcinolone)
 - ❑ Intranasal antihistamine (e.g., azelastine, olopatadine)
 - ❑ Oral antihistamine (e.g., levocetirizine)
 - ❑ Leukotriene inhibitor (e.g., montelukast, zafirlukast)
- ❑ Provider has prescribed auto-injectable epinephrine (**verified by chart notes or pharmacy paid claims**)
 - Provider attests that member does **NOT** have any of the following:
 - Receiving concomitant therapy with other allergen immunotherapy products (review chart notes for documentation of concurrent use of allergy shots)
 - History of severe, unstable or uncontrolled asthma: (review claims documenting Xolair + med/high dose of an inhaled corticosteroid/Long-acting beta agonist on file)
 - History of severe systemic allergic reaction (review claims documenting Hereditary Angioedema (HAE) medications)
 - History of eosinophilic esophagitis

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.